Covid-19: Should doctors recommend treatments and vaccines when full data are not publicly available?
RM Johnson, P Doshi, D Healy - bmj, 2020 - bmj.com
RM Johnson, P Doshi, D Healy
bmj, 2020•bmj.comWith knowledge of covid-19 less than a year old, treatment remains fraught with uncertainty.
Preprint data and adaptive clinical trials are imperfect but can guide active decision making
in life-or-death situations, says Raymond M Johnson. But Peter Doshi and David Healy
argue that doctors and professional societies should state that, without complete data
transparency, they will not endorse covid-19 products as being based on science
Preprint data and adaptive clinical trials are imperfect but can guide active decision making
in life-or-death situations, says Raymond M Johnson. But Peter Doshi and David Healy
argue that doctors and professional societies should state that, without complete data
transparency, they will not endorse covid-19 products as being based on science
With knowledge of covid-19 less than a year old, treatment remains fraught with uncertainty. Preprint data and adaptive clinical trials are imperfect but can guide active decision making in life-or-death situations, says Raymond M Johnson. But Peter Doshi and David Healy argue that doctors and professional societies should state that, without complete data transparency, they will not endorse covid-19 products as being based on science
bmj.com